苯甲酸氨氯地平 | 1239916-29-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 苯甲酸氨氯地平
• 英文名称: amlodipine benzoate
• 英文别名: benzoic acid;3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
• CAS: 1239916-29-0
• 化学式: C₇H₆O₂*C₂₀H₂₅ClN₂O₅
• 分子量: 531.005
• InChiKey: RVPCEXXEUXIPEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.65
• 重原子数：
  37
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  137
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  sodium benzoate 、 苯磺酸氨氯地平 在 polysorbate 80 作用下， 以 水 为溶剂， 生成 苯甲酸氨氯地平
  参考文献：
  名称：

  AMLODIPINE FORMULATIONS

  摘要：

  在此提供了稳定的氨氯地平液体制剂。同时还提供了使用氨氯地平液体制剂治疗某些疾病（包括高血压和冠状动脉疾病）的方法。

  公开号：

  US20190314279A1

文献信息

• Amlodipine formulations
  申请人：Silvergate Pharmaceuticals, Inc.

  公开号：US10695329B2

  公开（公告）日：2020-06-30

  Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

  本文提供了稳定的氨氯地平口服液制剂。本文还提供了使用氨氯地平口服液制剂治疗某些疾病（包括高血压和冠心病）的方法。
• Pharmaceutical solution of amlodipine
  申请人：LIQMEDS WORLDWIDE LIMITED

  公开号：US11253474B1

  公开（公告）日：2022-02-22

  Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

  本文公开了一种基本不含水的液体药物制剂，包含：(i) 氨氯地平或其药学上可接受的盐；(ii) 至少一种药学上可接受的赋形剂；(iii) 足量的包含甘油的载体。本文还公开了一种基本上不含水和乙醇的液体药物制剂，包括：(i) 氨氯地平或其药学上可接受的盐；(ii) 至少一种药学上可接受的赋形剂；(iii) 足量的由甘油组成的载体。
• AMLJODIPINE FORMULATIONS
  申请人：Silvergate Pharmaceuticals, Inc.

  公开号：US20210023003A1

  公开（公告）日：2021-01-28

  Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
• [EN] (S)-AMLODIPINE MALATE<br/>[FR] (S)-AMLODIPINE MALATE
  申请人：SEPRACOR INC

  公开号：WO2005089353A2

  公开（公告）日：2005-09-29

  One aspect of the present invention relates to optically pur (S)-amlodipine malate. Another aspect of the present invention relates to (rac)-amlopidine malate. In a preferred embodiment, compound is optically pure (S)-amlodipine L-malate. Another aspect of the present invention relates to a pharmaceutical composition comprising optically pure (S)-amlodipine malate. Another aspect of the present invention relates to a method of preparing optically pure (S)-amlodipine malate, comprising admixing optically pure (S)-amlodipine with malic acid. Another aspect of the present invention relates to the various polymorphic and solvated forms of optically pure (S)-amlodipine malate. In another prefered embodiment the invention relates to polymorphic and solvated forms A-G. The present invention also relates to a method of preparing optically pure (S)-amlodipine malate, comprising combining a salt of optically pure (S)-amlodipine with a malate salt to give optically pure (S)-amlodipine malate. In a preferred embodiment, the malate salt is an optically pure L-malate salt.
• [EN] AMLODIPINE FORMULATIONS<br/>[FR] FORMULATIONS D'AMLODIPINE
  申请人：SILVERGATE PHARMACEUTICALS INC

  公开号：WO2018067959A1

  公开（公告）日：2018-04-12

  Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).